297 related articles for article (PubMed ID: 29064152)
1. Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination.
Kasarala G; Choi S; Lopez K; Britt RB; Boatright C; Tillmann HL
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29064152
[No Abstract] [Full Text] [Related]
2. Hepatitis C genotype change after transplantation utilizing hepatitis C positive donor organs.
Adekunle R; Jonchhe S; Ravichandran B; Wilson E; Husson J
Transpl Infect Dis; 2018 Aug; 20(4):e12925. PubMed ID: 29797655
[TBL] [Abstract][Full Text] [Related]
3. Acute liver graft cellular rejection after interferon-free antiviral treatment for HCV infection. Is there a risk? A warning about three cases.
Dahlqvist G; Horsmans Y; Komuta M; Coubeau L
Acta Gastroenterol Belg; 2019; 82(1):53-56. PubMed ID: 30888754
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.
Vukotic R; Conti F; Fagiuoli S; Morelli MC; Pasulo L; Colpani M; Foschi FG; Berardi S; Pianta P; Mangano M; Donato MF; Malinverno F; Monico S; Tamè M; Mazzella G; Belli LS; Viganò R; Carrai P; Burra P; Russo FP; Lenci I; Toniutto P; Merli M; Loiacono L; Iemmolo R; Degli Antoni AM; Romano A; Picciotto A; Rendina M; Andreone P;
J Viral Hepat; 2017 Oct; 24(10):858-864. PubMed ID: 28370880
[TBL] [Abstract][Full Text] [Related]
5. Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study.
Dharancy S; Coilly A; Fougerou-Leurent C; Duvoux C; Kamar N; Leroy V; Tran A; Houssel-Debry P; Canva V; Moreno C; Conti F; Dumortier J; Di Martino V; Radenne S; De Ledinghen V; D'Alteroche L; Silvain C; Besch C; Perré P; Botta-Fridlund D; Francoz C; Habersetzer F; Montialoux H; Abergel A; Debette-Gratien M; Rohel A; Rossignol E; Samuel D; Duclos-Vallée JC; Pageaux GP;
Am J Transplant; 2017 Nov; 17(11):2869-2878. PubMed ID: 28898563
[TBL] [Abstract][Full Text] [Related]
6. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.
Grassi A; Ballardini G
World J Gastroenterol; 2014 Aug; 20(32):11095-115. PubMed ID: 25170198
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
[TBL] [Abstract][Full Text] [Related]
8. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
Korda D; Lenard ZM; Gerlei Z; Jakab Z; Haboub-Sandil A; Wagner L; Varga M; Cseprekal O; Marton A; Horvathy D; Takacs S; Doros A; Mathe Z
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):27-32. PubMed ID: 29049126
[TBL] [Abstract][Full Text] [Related]
9. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver-kidney transplant recipients.
Nookala AU; Crismale J; Schiano T; Te H; Ahn J; Robertazzi S; Rodigas C; Satoskar R; Kc M; Hassan M; Smith C
Clin Transplant; 2018 Mar; 32(3):e13198. PubMed ID: 29323755
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation.
Venturi C; Bueno J; Castells L; Quintero J; Casas I; Allende H; Martinez-Ibañez V; Charco R
Liver Transpl; 2011 Dec; 17(12):1474-80. PubMed ID: 21932378
[TBL] [Abstract][Full Text] [Related]
12. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
Ueda Y; Uemoto S
Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
[TBL] [Abstract][Full Text] [Related]
13. Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy.
Chan C; Schiano T; Agudelo E; Paul Haydek J; Hoteit M; Laurito MP; Norvell JP; Terrault N; Verna EC; Yang A; Levitsky J
Am J Transplant; 2018 Oct; 18(10):2506-2512. PubMed ID: 30075485
[TBL] [Abstract][Full Text] [Related]
14. Management of hepatitis C infection before and after liver transplantation.
Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
[TBL] [Abstract][Full Text] [Related]
15. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
[TBL] [Abstract][Full Text] [Related]
16. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
Kwok RM; Ahn J; Schiano TD; Te HS; Potosky DR; Tierney A; Satoskar R; Robertazzi S; Rodigas C; Lee Sang M; Wiegel J; Patel N; Gripshover J; Hassan MA; Branch A; Smith CI
Liver Transpl; 2016 Nov; 22(11):1536-1543. PubMed ID: 27543748
[TBL] [Abstract][Full Text] [Related]
19. Management of hepatitis C patients with decompensated liver disease.
Hsu CS; Kao JH
Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):679-88. PubMed ID: 26782619
[TBL] [Abstract][Full Text] [Related]
20. Effect of ezetimibe in HCV viral load after liver transplantation.
Monrroy-Bravo H; Angulo J; Pino K; Labbé P; López-Lastra M; Soza A
Ann Hepatol; 2016; 15(5):803-5. PubMed ID: 27493122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
